SymBio Pharmaceuticals Limited
4582.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.16 | 0.10 | -0.05 | 0.10 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -4.76 | -6.54 | -3.90 | -4.86 |
| Quality | ||||
| ROIC | -29.56% | -26.84% | -28.50% | -25.84% |
| Gross Margin | 62.28% | 76.10% | 76.66% | 77.33% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -40.03% | -39.78% | -38.78% | -37.42% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.96 | 1.76 | 2.33 | 3.73 |
| Interest Coverage | -40.82 | -19.07 | -20.44 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.37 | 0.33 | 0.24 | 0.53 |
| Cash Conversion Cycle | 297.79 | -14.56 | 446.96 | 239.75 |